Genmab A/S (OTCMKTS:GNMSF) Sees Unusually-High Trading Volume – Here’s What Happened

Genmab A/S (OTCMKTS:GNMSFGet Free Report) saw unusually-strong trading volume on Friday . Approximately 4,001 shares traded hands during mid-day trading, an increase of 69% from the previous session’s volume of 2,361 shares.The stock last traded at $336.45 and had previously closed at $335.77.

Genmab A/S Trading Down 1.7%

The stock has a market cap of $21.80 billion, a price-to-earnings ratio of 16.57 and a beta of 0.95. The company has a fifty day simple moving average of $256.77 and a 200-day simple moving average of $222.27.

Genmab A/S (OTCMKTS:GNMSFGet Free Report) last announced its earnings results on Thursday, August 7th. The company reported $5.42 EPS for the quarter, topping the consensus estimate of $3.99 by $1.43. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The company had revenue of $925.00 million during the quarter, compared to analysts’ expectations of $949.06 million.

About Genmab A/S

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Further Reading

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.